pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,885 catalysts · 4,876 phase readout · 2,350 8k filing · 286 earnings · 275 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 12 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: patent expiry×type: phase readout×clear all
type
  • phase readout4,876
  • 8k filing2,350
  • earnings286
  • pdufa275
  • phase 2 completion166
  • phase 1 completion71
phase 2 initiation
54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Infectious Disease7
    • Dermatology1
    • Oncology1

    Date TBD

    50
    ›RECRUITINGphase readoutNCT05755087: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

    Sponsor: Lapo Alinari. Phase: PHASE1. Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05660187: VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS)

    Sponsor: The Cleveland Clinic. Phase: NA. Conditions: Multiple Sclerosis

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07214987: PDT For Induction Therapy For Head And Neck Cancer

    Sponsor: Massachusetts General Hospital. Phase: PHASE2. Conditions: Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04640987: Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

    Sponsor: Porteus, Matthew, MD. Phase: PHASE1. Conditions: Hematologic Diseases

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07547787: A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

    Sponsor: Akeso. Phase: . Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07470593: Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.

    Sponsor: University Hospital, Strasbourg, France. Phase: . Conditions: Type 1 Diabetes (T1D)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07094893: Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

    Sponsor: Gruppo Oncologico del Nord-Ovest. Phase: PHASE4. Conditions: Colorectal Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06044493: MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

    Sponsor: Chong Kun Dang Pharmaceutical. Phase: PHASE4. Conditions: Kidney Transplant

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05411393: Synergizing Home Health Rehabilitation Therapy

    Sponsor: University of Florida. Phase: NA. Conditions: Frailty, Frail Elderly, Occupational Therapy, Activities of Daily Living, Home Health Care, Functional Status, Physical Functional Performance, Rehabilitation, Treatment Outcome, Health Services for the Aged

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04467021: Cancer and Blood Pressure Management, CARISMA Study

    Sponsor: ECOG-ACRIN Cancer Research Group. Phase: NA. Conditions: Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07005414: Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models

    Sponsor: Fei Li. Phase: PHASE2. Conditions: Autism Spectrum Disorder

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06391814: Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

    Sponsor: Ciusss de L'Est de l'Île de Montréal. Phase: NA. Conditions: EBV Associated Lymphoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06957314: A Study of Hospital-at-Home for People Receiving Tarlatamab

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: NA. Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT00131014: Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

    Sponsor: Dana-Farber Cancer Institute. Phase: . Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03256916: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix

    Sponsor: Tata Memorial Hospital. Phase: PHASE3. Conditions: Carcinoma Cervix,Stage III

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03093116: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    Sponsor: Turning Point Therapeutics, Inc.. Phase: PHASE1. Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07345806: A Pilot Study on an ACT-Based Program for Individuals With Special Needs and Their Caregivers

    Sponsor: The University of Hong Kong. Phase: NA. Conditions: Parenting Stress, Psychological Flexibility

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT00581906: Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: . Conditions: Head and Neck Cancer

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT07071584: Evaluation of a Multi-electrode Prosthesis Control System for Real-world Tasks Performance in Individuals With Upper Limb Transradial Amputation

    Sponsor: Phantom Neuro Inc.. Phase: NA. Conditions: Upper Limb Amputation Below Elbow

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03293784: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma

    Sponsor: Institut Claudius Regaud. Phase: PHASE1. Conditions: Melanoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06582784: IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)

    Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Depression, Depressive Symptoms, Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06467084: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

    Sponsor: KalVista Pharmaceuticals, Ltd.. Phase: PHASE3. Conditions: Hereditary Angioedema

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07110233: Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

    Sponsor: University of California, San Francisco. Phase: NA. Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05327452: Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study

    Sponsor: Dana-Farber Cancer Institute. Phase: NA. Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07411352: Left Lateral Position vs Supine Position to Reduce Active Labor Duration

    Sponsor: Universidad Nacional Autonoma de Honduras. Phase: NA. Conditions: Labor Pain

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07225647: A Study to Assess the Effect of Food on the Drug Levels of Admilparant

    Sponsor: Bristol-Myers Squibb. Phase: PHASE1. Conditions: Healthy Participants

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06459947: Effect of Cyanoacrylate and Concentrated Growth Factor on Palatal Donor Site

    Sponsor: Yuzuncu Yil University. Phase: NA. Conditions: Wound Healing, Pain, Patient Comfort

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07498647: Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia

    Sponsor: BioRay Pharmaceutical Co., Ltd.. Phase: PHASE2. Conditions: Gout and Hyperuricemia

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT05341349: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

    Sponsor: Emory University. Phase: PHASE1. Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07470749: Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh

    Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Phase: . Conditions: MAFLD, Metabolic Abnormalities, Obesity & Overweight

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04837833: An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: NA. Conditions: Pancreas Cancer, Gastrointestinal Adenocarcinoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05306938: Adolescent Wellness Visits in Tanzania

    Sponsor: University of North Carolina, Chapel Hill. Phase: NA. Conditions: HIV Testing, Contraceptive Usage

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07489352: N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure

    Sponsor: Brigham and Women's Hospital. Phase: NA. Conditions: Heart Failure, Beta-blocker, Older Adults

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07523152: Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study

    Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle. Phase: NA. Conditions: Pelvic Cancer, Anal Cancer, Vaginal Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04279158: Attention Modulation of Local and Global Inhibition Mechanisms

    Sponsor: Hospices Civils de Lyon. Phase: NA. Conditions: Optical Phenomena

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07118358: BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

    Sponsor: Biotronik, Inc.. Phase: NA. Conditions: Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04395131: Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease

    Sponsor: Mozarc Medical US LLC. Phase: NA. Conditions: End-stage Renal Disease

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07386145: Frequency and Voluntary Contraction-Dependent Activation of Tonic Vibration Reflex and Bone Myoregulation Reflex

    Sponsor: Istanbul Physical Medicine Rehabilitation Training and Research Hospital. Phase: NA. Conditions: Whole Body Vibration

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT01424345: The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

    Sponsor: CAMC Health System. Phase: PHASE4. Conditions: Kidney Transplant Immunosuppression

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07474272: Non-Surgical Treatment of Periodontitis With Adjunctive Sodium Hypochlorite/Amino Acids and Cross-Linked Hyaluronic Acid

    Sponsor: Marwan El Mobadder. Phase: NA. Conditions: Periodontitis

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT02879175: Patients' Follow-up After Subarachnoid Haemorrhage Caused by Ruptured Intracranial Aneurysms

    Sponsor: Fondation Ophtalmologique Adolphe de Rothschild. Phase: . Conditions: Intracranial Aneurysms

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05669001: A Study of TCD601 in de Novo Renal Transplant Recipients

    Sponsor: ITB-Med LLC. Phase: PHASE2. Conditions: Renal Transplantation

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06407193: Gastric Emptying After Sleeve Gastrectomy

    Sponsor: Rijnstate Hospital. Phase: . Conditions: Gastric Emptying, Bariatric Surgery

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07433621: Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

    Sponsor: Children's Hospital Medical Center, Cincinnati. Phase: PHASE1. Conditions: XIAP Deficiency

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02583893: Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

    Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Phase: PHASE2. Conditions: Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT01719016: Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics

    Sponsor: University of Cincinnati. Phase: . Conditions: Coronary Artery Disease

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07435506: Effects of Feedback and Aging on Aiming Movements in Virtual Reality

    Sponsor: Aix Marseille Université. Phase: NA. Conditions: Healthy Older Adults, Healthy Young Adults

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07323706: Ayurvedic Diet in Myxedema

    Sponsor: University of Copenhagen. Phase: NA. Conditions: Hypothyroidism Primary

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07453004: A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

    Sponsor: TJ Biopharma Co., Ltd.. Phase: PHASE2. Conditions: Acute Gouty Arthritis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05170984: MAtrix Therapy for Hard-to-heal ChrOnic Wounds

    Sponsor: Organ, Tissue, Regeneration, Repair and Replacement. Phase: NA. Conditions: Chronic Ulcer of Leg or Foot, Diabetic Foot Ulcer, Arterial Ulcer, Venous Ulcer of Leg

    full page →ctgov ↗
    ← prev
    page 36 of 98
    next →